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Purpose: Granulocyte-colony stimulating factors (G-CSFs) are widely used to mobilize
CD34+ stem cells and to support the engraftment after hematopoietic stem cell transplanta-
tion (HSCT). A budget impact analysis and an incremental cost-effectiveness study of two
G-CSFs (Lenograstim and Filgrastim biosimilar), considering engraftment, number of hos-
pitalization days and number of G-CSF vials administered were performed.
Patients and Methods: Between 2009 and 2016, 248 patients undergoing autologous
HSCT have been evaluated and divided into three groups (100 Leno-Leno, 93 Leno-Fil,
55 Fil-Fil) according to the type of G-CSF used for hematopoietic stem cell mobilization and
hematopoietic stem cell recovery after transplant.
Results: The following statistically significant differences have been observed between Leno-
Leno, Leno-Fil, Fil-Fil groups: a higher number of harvested CD34+ cells (10.56 vs 8.00 vs 7.20;
p=0.0003) and a lower number of G-CSF vials (8 vs 8 vs 9; p=0.00020) used for full bone marrow
recovery favoring Lenograstim. No statistically significant differences were found regarding the
number of G-CSF vials used for mobilization, apheresis number and CD34+ cell peak. The post-
transplant hematological recovery was faster in Lenograstim group than Filgrastim group: median
time to neutrophil count engraftment (>500/mmc) was 12 vs 13 days; median time for platelets
recovery (>20.000/mmc) was 12 vs 15 days (p=0.0001). The use of Lenograstim achieved cost
savings of €566/patient over Filgrastim biosimilar, related to a decreased number of days of
hospitalization (16 vs 17 days; p=0.00012), a lower overall incidence of adverse events, laboratory
tests, transfusions for platelet recovery following discharge.
Conclusion: In our experience, Lenograstim outperforms Filgrastim in terms of effective-
ness and lower cost. This study shows a clinical superiority of Lenograstim over Filgrastim
suggesting a potential cost savings favoring Lenograstim.
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Introduction
In the current clinical practice, dose-intensive chemotherapy followed by peripheral
blood stem cell transplantation (PBSCT) is a procedure commonly performed in the
treatment of a variety of hematological malignancies.1,2
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Use of granulocyte-colony stimulating factor (G-CSF)-
mobilized peripheral blood stem cells (PBSCs) has replaced
bone marrow as a source of stem cells for both autologous
and allogeneic hematopoietic stem cell transplantation
(HSCT).1 G-CSFs remain the most commonly used agent
for hematopoietic stem cells (HSCs) mobilization in the
clinic. G-CSFs are biological growth factors that promote
the proliferation, differentiation and activation of neutrophils
in the bone marrow.3 Currently, four chemically different
formulations of recombinant human (rh) G-CSF are commer-
cially available in Europe: glycosylated (Lenograstim), non-
glycosylated (Filgrastim), pegylated (Pegfilgrastim) and gly-
copegylated (Lipegfilgrastim).4–7 All different formulations
are indicated to reduce duration of neutropenia and incidence
of febrile neutropenia in patients with non-myeloid malig-
nancies receiving myelosuppressive chemotherapy.7–9
Lenograstim and Filgrastim are short-acting G-CSFs
commonly administered in the transplant setting, either
for mobilization of HSCs out of bone marrow into periph-
eral blood or as supportive care after autologous or allo-
geneic transplantation. Lenograstim, derived from Chinese
hamster ovary cells, is indistinguishable from the human
endogenous glycoprotein, while Filgrastim is produced in
Escherichia coli bacterial cells, therefore is non-
glycosylated and carries an extra Methionine at the
N-terminal end of the peptide chain as compared to
Lenograstim. Both are used to treat chemotherapy-
induced febrile neutropenia, in PBSCs mobilization and
in promoting recovery after autologous HSCT.3,8,9 In vitro
and ex vivo studies have shown biological differences
between Lenograstim and Filgrastim with particular
emphasis on the quality of activated neutrophils. In clin-
ical practice, these differences translate into a lower inci-
dence of febrile episodes and increased CD34+
mobilization efficacy upon Lenograstim administration
compared with Filgrastim, and therefore, a clinical super-
iority of Lenograstim has been postulated.10,11
Biosimilars are non-identical version of the biopharma-
ceutical originator that may vary in terms of size of the
active substance, complexity and nature of the manufac-
turing process. Numerous biosimilar G-CSFs have been
approved in Europe and introduced in clinical practice.12
Although the paucity of data supporting clinical equiva-
lence in terms of efficacy, safety and immunogenicity, the
European Medicines Agency (EMA) declared the thera-
peutic equivalence of biosimilars for PBSC mobilization
and recovery after autologous HSCT.3,8,9
Considering that biological differences can translate
into different clinical outcomes, the objective of this ana-
lysis was assessing the effectiveness of Lenograstim ver-
sus Filgrastim for PBSC mobilization and hematopoietic
recovery after transplantation and the related costs in a real
clinical setting.
Patients and Methods
At Azienda Ospedaliera Universitaria Integrata in Verona
(Italy), a retrospective comparative study has been carried
out involving 248 consecutive patients with multiple mye-
loma, non-Hodgkin lymphoma or Hodgkin lymphoma
undergoing mobilization and subsequent autologous
HSCT between January 2009 and June 2016. Our retro-
spective database analysis has been conducted in accor-
dance with the Declaration of Helsinki, and informed
consent was not required due to the anonymous and retro-
spective design of the data collection. The analysis has
been notified to the ethical committee of Azienda
Ospedaliera Universitaria Integrata di Verona that received
and approved the study. And it was approved by the local
institutional review board. Eligible patients were assigned
to three groups based on availability of G-CSF used for
HSC mobilization and post-transplantation recovery: 100
patients treated with Lenograstim for both mobilization
and hematological recovery (Leno-Leno group); 93
patients initially treated with Lenograstim and then with
Filgrastim biosimilar (Leno-Fil group); 55 patients treated
with Filgrastim biosimilar for both mobilization and post-
transplantation support (Fil-Fil group). Patient's character-
istics in terms of age, sex and type of tumor were well
balanced between the three treatment groups. Baseline
patient characteristics are summarized in Table 1.
Patients were mobilized with 5 µg/kg G-CSF
(Lenograstim or Filgrastim biosimilar) for nine days per
standard procedure, regardless of leukocyte and CD34+
count, and the collection of PBSCs was performed by
apheresis at the ninth day. In the case of mobilization
failure, patients underwent G-CSF stimulation for two
additional days followed by subsequent apheresis until
mobilization has reached an optimal level, defined as
more than 2.5 x 106 CD34+ cells/kg. All the patients
received also chemotherapy for mobilization: all patients
with multiple myeloma and Hodgkin lymphoma received
cytoxan 3g/sqm, while patients with Non-Hodgkin lym-
phoma received either cytoxan 3g/sqm or DHAP regimen.
Malignancies and different regimens were balanced among
the three groups.
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The CD34+ cell collection was followed by the con-
ditioning regimen that reduces tumor burden and sup-
presses the recipient immune system, allowing stem cell
engraftment. As conditioning regimes, all myeloma
patients received Melphalan 200 mg/sqm i.v. in 4 doses
on day −3 from transplant, while lymphoma patients
were conditioned with Mitoxantrone 60 mg/sqm i.v.
on day −5 and Melphalan 160 mg/sqm i.v. on day −4.
The conditioning was followed by infusion of autologous
CD34+ stem cells. G-CSF was started on day +4 after
transplant and continued until hematological recovery.
Patients were then discharged from the hospital after
reaching a complete recovery of their neutrophils number
(>500/mmc). Once discharged, patients received
a follow-up visit every two days (with a maximum of
three visits per week) to control their platelet level and
receive, if necessary, a blood transfusion, until complete
recovery of platelets (>20,000/µL).
The clinical variables collected in the analysis to assess
the effectiveness of each G-CSF were the number of G-CSF
vials used for the recovery, the number of days from the first
G-CSF administration to neutrophil recovery (>500/mmc),
the number of days from the first G-CSF administration to
platelet recovery (>20,000/µL) and the percentage of patients
developing pneumonia, fever and sepsis.
The economic analysis was conducted according to the
Regional Health Service policies and procedures and con-
sidering the sole differential costs between the three groups
of patients (ie, Leno-Leno, Leno-Fil, Fil-Fil). The costs taken
into account, referred to year 2016, were those related to
aphereses, inpatient stay, adverse events management and
G-CSF administration. The cost reported in Table 2 was
then multiplied by the median number of aphereses,
inpatient day, adverse events, platelet transfusions and
G-CSF vial used in each group, to assess the differential
economic impact of the use of different G-CSFs.
Statistical Analysis
All statistical analyses were performed using the proce-
dures of SAS version 9.4. A two-tailed p-value of 0·05 or
less was chosen to define statistically significant results.
Statistical analyses were carried out by comparing the
three groups against each other (pairwise comparisons)
and by looking for the presence of a linear trend between
Leno-Leno, Leno-Fil, Fil-Fil groups in this order.
Means, medians, standard deviations, minimum and
maximum values were used to summarize continuous and
count variables (number of harvested CD34+ cells/number of
aphereses, CD34+ cell peak, number of G-CSF vials, etc.).
Statistical comparison across the three groups was performed
using a Non-Parametric ANOVA following rank transforma-
tion of data.
Times to event variables (time to WBC > 500, time to
PTLS > 20,000, hospitalization days, days of fever, etc.) were
described using the Kaplan–Meier method and compared
using the Peto Log-rank test. Percentages were used to sum-
marize categorical variables (number of aphereses, pneumo-
nia, sepsis, etc.), while statistical comparison across the three
groups was carried out using Fisher’s Exact Test.
Results
Two-hundred forty-eight patients have been included in
the analysis: 100 patients in the Leno-Leno group, 93
patients in the Leno-Fil group and 55 patients in the Fil-
Table 1 Characteristics of the Study Population
Variable Leno (n=100) Leno – Fil (n=93) FIL (n=55) All Patients (n=248) P-value
Age at mobilization
Mean ± SD 50.46±13.84 53.74±11.64 50.25±15.64 51.64±13.54 0.1665
Median (Min - Max) 53.29 (9.06–70.63) 57.00 (13.8–69.79) 54.59 (9.07–70.25) 55.9 (9.06–70.63)
Sex (%)
Female 31.0 37.6 43.6 36.3 0.2771
Male 69.0 62.4 56.4 63.7
Type of tumor (%)
Hodgkin’s Lymphoma 17.0 11.8 9.1 13.3 0.2739
Multiple Myeloma 41.0 49.5 40.0 44.0
Non-Hodgkin’s Lymphoma 36.0 37.6 41.8 37.9
Pediatric Lymphomas 5.0 1.1 9.1 4.4
Solid Tumors 1.0 0.0 0.0 0.4
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Fil group. Effectiveness of HSC mobilization was evalu-
ated considering the following variables: number of
G-CSF vials administered, number of aphereses per-
formed, number of harvested CD34+ cells and CD34+
cell peak. As reported in Table 3, a significantly higher
number of harvested CD34+ cells were observed in
patients treated with Lenograstim (Leno-Leno and Leno-
Fil groups) compared to patients treated with Filgrastim
(Fil-Fil group): the mean number of harvested CD34+ cells
was 10.10 ± 5.87 x106 cells/kg for Leno-Leno/Leno-Fil
groups and 7.92 ± 3.9 x106 cells/kg for Fil-Fil group
(p=0.0101). No differences were observed between
Lenograstim and Filgrastim in terms of number of vials
needed to obtain CD34+ cell mobilization, number of
aphereses and CD34+ cell peak. The mean number of
G-CSF vials administered was 10.34 ± 1.58 for the Leno-
Leno/Leno-Fil groups and 10.13 ± 1.32 for the Fil-Fil
group without statistically significant differences
(p=0.3691); the mean number of aphereses was 1.66 ±
0.78 for the Leno-Leno/Leno-Fil groups and 1.56 ± 0.66
for the Fil-Fil group (p=0.3872); the mean of CD34+ cell
peak was 112.86 ± 123.55/µL for the Leno-Leno/Leno-Fil
groups and 89.49 ± 87.21/µL for the Fil-Fil group
(p=0.1908).
A statistically significant difference has been detected in
terms of days from chemotherapy required to obtain white
blood cell (WBC) and platelet (PTL) recovery, defined as
days after starting the treatment until stable hematological
recovery. Engraftment was defined as ANC>500/mmc and
platelet count >20,000/mmc. Particularly, the post-transplant
hematological recovery was faster in the Leno-Leno group
compared with the Fil-Fil group: median neutrophil >500/
mmc (12 vs 13 days; p=0.00012), median platelets >20.000/
Table 2 Cost Data Considered in the Analysis
Cost Element Cost
(€)
Source
Apheresis 1423.20a Expert opinion based on
hospital financial department’s
data
Inpatient day 822.62b Italian Ministry of Economy
and Finance
Adverse events’
management
500.00c Expert opinion based on
hospital financial department’s
data
Outpatients activities
for platelets’
transfusion
35.00d Expert opinion based on
hospital financial department’s
data
Platelets’ transfusion 80.00e Expert opinion based on
hospital financial department’s
data
Lenograstim vial 50.59
Filgrastim vial 17.03
Notes: a413.20 € for apheresis (code 99.75 “Aferesi per raccolta cellule staminali”
- Annex A - Decreto 47 del 22 maggio 2013 Regione Veneto) plus 1000 € for
plasma freezing. bThe cost per inpatient day was estimated starting from data
published by the Italian Ministry of Economy and Finance and discounted to its
2016 value, considering the yearly inflation at average consumer prices, as reported
by the International Monetary Fund. cThe cost to manage adverse events was
calculated considering ten days within the hospital “Diagnostic Integrated Clinic”.
The mean cost per daily hematologic tests and specialist visit was estimated by the
hospital financial department in 50 €. dFor each transfusion, an outpatient visit is
performed along with blood tests and other laboratory analysis (code 89.01.F
“Visita oncologica di controllo” and code 90.62.2 “Emocromo: Hb, GR, GB, HCT,
PLT, Ind. Deriv., F. L.” - Annex A - Decreto 47 del 22 maggio 2013 Regione Veneto);
expert opinion based on hospital financial department’s data. eFor each transfusion,
five blood units were considered, based on expert’s opinion.
Table 3 Efficacy of the Mobilization Process
Variable Lenograstim
Leno-Leno +
Leno-Fil
(N=193)
Filgrastim
Fil-Fil
(N=55)
P-value
Number of G-CSF vials used for mobilization
Mean ± SD (N) 10.34±1.58 (193) 10.13±1.32
(55)
0.3691
Number of Aphereses
Mean ± SD (N) 1.66±0.78 (193) 1.56±0.66
(55)
0.3872
Number of harvested CD34+ cells/Number of Aphereses
(x 106 cells/kg)
Mean ± SD (N) 10.10±5.87 (193) 7.92±3.9
(55)
0.0101
Median (Min - Max) 9.33 (1.25–41.72) 7.20
(1.62–20.19)
CD34+ cell peak/microL
Mean ± SD (N) 112.86±123.55
(193)
89.49±87.21
(55)
0.1908
Median (Min - Max) 73.13 (0–1101.76) 52.48
(0–411.7)
Number of Aphereses
1 49.2 (95/193) 52.7 (29/55)
2 38.9 (75/193) 38.2 (21/55)
3 8.8 (17/193) 9.1 (5/55)
4 2.6 (5/193) 0.0 (0/55)
5 0.5 (1/193) 0.0 (0/55)
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mmc (12 vs 15 days; p=0.0001). The use of Lenograstim
instead of Filgrastim led to a decreased number of days of
hospitalization (median: 16 vs 17; p=0.00012) and number of
G-CSF vials used for full bone marrow recovery (median: 8 vs
9; p=0.00020) (Table 4). Figure 1 shows the Kaplan–Meier
curves of the three treatment groups in relation to days from
chemotherapy necessary for WBC (>500/mmc) and PTL
(>20.000/mmc) recovery and days of hospitalization.
Regarding the adverse events (AEs), patients treated with
Lenograstim showed a lower incidence of fever (p=0.01834)
than Filgrastim group (Table 4).
When compared with Filgrastim-based treatment, the
use of Lenograstim for both mobilization and bone mar-
row recovery (Leno-Leno group versus Fil-Fil group)
resulted in a decrease of costs for the total patient’s man-
agement of −566€, considering the median values of clin-
ical outcomes. This is mainly due to cost reduction in
terms of median inpatient days (−822 €), median adverse
event incidence (−182 €), median laboratory tests and
median of transfusions for platelet recovery following
discharge (-€115). The cost containment due to the
aforementioned activities counterbalances the higher vial
cost of Lenograstim (+302 € for mobilization and +251 €
for bone marrow recovery).
The same economic analysis between the Leno-Leno
group and the Leno-Fil group shows similar results. The use
of Lenograstim for both mobilization and bone marrow recov-
ery led to lower costs compared with the use of Lenograstim
for mobilization and Filgrastim for bone marrow recovery, of
−59 €. The reduction of costs is related to vials used for
mobilization (−101 €) and to adverse event management
(−226 €), while additional costs are due to vials used for
bone marrow recovery (+268 €). This analysis revealed
a clinical superiority of Lenograstim over Filgrastim that can
translate into potential cost savings for the National Health
Service.
Discussion
Recombinant human G-CSFs have become a clinical tool
widely used by hematologists and oncologists for neutro-
phil recovery after myelotoxic chemotherapy in cancer
Table 4 Efficacy of the Post-Transplant Hematological Recovery
Variable Leno (N=100) Leno–Fil (N=93) Fil (N=55) All Patient (N=248) P-value for Linear Trend
Days from chemotherapy necessary to obtain White Blood Cells recovery (N > 500) Fil → Leno-Fil→ Leno
Mean ± SD (N) 12.13±1.88 (100) 12.90±2.32 (93) 13.69±3.44 (55) 12.77±2.52 (248) 0.00012
Median (Min - Max) 12 (10–25) 12 (9–21) 13 (10–28) 12 (9–28)
Days from chemotherapy necessary to obtain Platelets recovery (PTLS > 20.000) 0.0001
Mean ± SD (N) 13.11±3.45 (100) 15.89±9.24 (93) 17.69±8.35 (55) 15.17±7.43 (248)
Median (Min - Max) 12 (10–30) 13 (8–90) 15 (10–51) 13 (8–90)
Days of hospitalization 0.00012
Mean ± SD (N) 16.13±1.88 (100) 16.90±2.32 (93) 17.69±3.44 (55) 16.77±2.52 (248)
Median (Min - Max) 16 (14–29) 16 (13–25) 17 (14–32) 16 (13–32)
Number of G-CSF vials for bone marrow recovery
Mean ± SD (N) 8.13±1.88 (100) 8.90±2.32 (93) 9.69±3.44 (55) 8.77±2.52 (248) 0.00020
Median (Min - Max) 8 (6–21) 8 (5–17) 9 (6–24) 8 (5–24)
Days of fever 0.42158
Mean ± SD (N) 1.70±2.69 (100) 2.70±3.01 (93) 2.09±2.69 (54) 2.16±2.84 (247)
Median (Min - Max) 0 (0–10) 2 (0–16) 1.5 (0–14) 0 (0–16)
Pneumonia 6.0% (6/100) 6.5% (6/93) 9.1% (5/55) 6.9% (17/248) 0.49684
Sepsis 16.0% (16/100) 20.4% (19/93) 14.5% (8/55) 17.3% (43/248) 0.96572
Fever 39.0% (39/100) 57.0% (53/93) 56.4% (31/55) 49.6% (123/248) 0.01834
Fever FUO 20.0% (20/100) 33.3% (31/93) 36.4% (20/55) 28.6% (71/248) 0.01891
Fever FKO 19.0% (19/100) 23.7% (22/93) 20.0% (11/55) 21.0% (52/248) 0.77149
Abbreviations: FUO, fever of unknown origin; FKO, fever of known origin.
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patients, for PBSC mobilization in individuals with hema-
tological malignancies and healthy donors and for poten-
tiation of stem cell engraftment after HSCT.13,14
The current G-CSF scenario in Europe includes
Lenograstim, Filgrastim and its biosimilars, Pegfilgrastim
and Lipegfilgrastim, whose availability represents an
important resource in cancer treatment. Since its patent
expired in 2006, several Filgrastim biosimilars have been
developed and approved, while no Lenograstim biosimilar
is currently available on the market. At present, data
regarding the use of G-CSF biosimilars in the context of
autologous HSCT for mobilization have been published
demonstrating a substantial equivalence in terms of stem
cell collection. However, few data are still available about
HSC mobilization from healthy donors.15,16 Moreover, in
2009 the Executive Committee of the European Bone
Marrow Transplantation (EBMT) recommended against
the use of G-CSF biosimilars for stem cell mobilization
in healthy donors.17 The same concern about the use of
biosimilars in normal donors was reported by World
Marrow Donor Association in 2011.15
The current economic context, resulting from the financial
crisis, led the National Health Service and the Health
Organizations to implement cost-effectiveness criteria in deci-
sion-making processes of health technology application. The
introduction of biosimilars into clinical practice has repre-
sented an important opportunity for cost reduction allowing
significant cost advantages for transplant unit. However,
although their development is strictly regulated, biosimilar
approval is based on clinical data extrapolated from the origi-
nator. Hence, concerns have been raised on switching between
biosimilars and their originator. Therefore, it is crucial to
choose the most appropriate G-CSF for specific clinical set-
tings. Indeed, economic criteria must be considered alongwith
scientific and clinical evidence and, for these reasons, it is
important to find a proper balance between cost, scientific data
and medical needs.
We compared Lenograstim and Filgrastim in terms of
economic impact and effectiveness in daily clinical practice
in patients with hematologic malignancies undergoing PBSC
mobilization and transplant. We analyzed differences in
terms of number of G-CSF vials administered, number of
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of hospitalization.
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aphereses performed, number of harvested CD34+ cells and
CD34+ cell peak in response to Lenograstim or Filgrastim to
determine which growth factor presented the best profile in
terms of effectiveness and cost. For the measured variables,
including number of harvested CD34+ cells, number of
G-CSF vials administered for bone marrow recovery and
time of engraftment, Lenograstim stimulation obtained better
results with a consequent positive effect on direct medical
cost. Similarly, earlier bone marrow recovery decreased hos-
pitalization time (16 vs 17 days) in patients mobilized with
Lenograstim. Our results are consistent with other clinical
trials comparing the different G-CSFs. Orciuolo and collea-
gues demonstrated a lower incidence of febrile episodes,
a much more effective stem cell mobilization and a higher
count of mobilized stem cells upon Lenograstim administra-
tion compared with Filgrastim.2 Ria and colleagues com-
pared the use of Lenograstim, Filgrastim and Pegfilgrastim
in 146 patients undergoing autologous HSCT for lympho-
proliferative disorders. Their results showed that
Lenograstim achieved an adequate mobilization and
a target collection faster and with fewer leukaphereses as
compared to Filgrastim and Pegfilgrastim.16
In our study, although the price of Lenograstim is
higher compared to Filgrastim biosimilar, the total medical
cost related to inpatient stay, management of adverse
events, laboratory tests, transfusions for for platelets and
recovery after discharge was lower due to faster post-
transplant hematological recovery, reduced use of G-CSF
vials and days of hospitalization observed in the cohort of
patients treated with Lenograstim (Table 5). The longer
hospitalization due to delayed hematological recovery and
complications (fever) counterbalances the cost of growth
factor administration.
This study has some limitations related to the observa-
tional, retrospective and single-institution design that may
confine the generalization of the results. Until results from
multi-center randomized clinical trials comparing the differ-
ent G-CSFs are reported, it is important to collect and
describe individual clinical experience to support the scien-
tific community to make decisions concerning the choice of
G-CSF, especially regarding the transplant setting. In this
regard, our findings suggest that Lenograstim administered
for HSC mobilization and hematopoietic stem cell recovery,
in patients with lymphoma and multiple myeloma under-
going chemotherapy and autologous HSCT, is associated
with a greater health benefit and lower cost, likely represent-
ing a cost-effective option over Filgrastim.
Conclusions
Our study demonstrated that in patients with lymphoma and
multiple myeloma undergoing chemotherapy and autologous
HSCT, Lenograstim accelerated neutrophil and platelet
recovery post-HSCT and shortened the duration of hospita-
lization. Lenograstim is an essential option in treatment of
chemotherapy-induced neutropenia, PBSC mobilization and
acceleration of hematological recovery. In conclusion, our
experience identified Lenograstim as the preferable cost-
saving G-CSF in comparison to Filgrastim.
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